NCT06478381View on ClinicalTrials.gov

L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Relapsed/Refractory B-cell Lymphomas
Interventions
DRUG

L218CAR19

L218CAR19 is intravenously administered at three dose levels.

Trial Locations (1)

450008

RECRUITING

Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV